Reply to U.R. Mansmann et al and M.-W. An et al

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4374-4375

  Claret, Laurent ^a   Bruno, René ^a  

^a Pharsight Consulting Services   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; HUMAN; LETTER; MEASUREMENT ERROR; METRIC SYSTEM; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TIME TO TUMOR GROWTH; TUMOR VOLUME; COLORECTAL NEOPLASMS; FEMALE; MALE; PATHOLOGY; COLORECTAL TUMOR; NOTE;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84892878057     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.5733     Document Type: Letter

References (9)

1. Mansmann UR, Laubender RP: Methodologic diligence is needed to define and validate tumor-size response metrics to predict overall survival in first-line metastatic colorectal cancer. J Clin Oncol 31:4373-4374, 2013
2. Claret L, Gupta M, Han K, et al: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013
3. Ibrahim JG, Chu H, Chen LM: Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol 28:2796-2801, 2010
4. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95, 2001
5. An M-W, Mandrekar SJ, Sargent DJ: Application of tumor measurement- based metrics in the real world. J Clin Oncol 31:4374, 2013
6. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
7. Stein AM, Carter A, Hollaender N, et al: Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. J Clin Oncol 29:314s, 2011 (suppl 15s; abstr 4602)
8. Quartino AL, Claret L, Li J, et al: Evaluation of tumor size metrics to predict survival in advanced gastric cancer. PAGE 22, 2013 (abstr 2812). www.page-meeting.org/?abstract-2812
9. Bruno R, Mercier F, Claret L: Model-based drug development in oncology: What's next? Clin Pharmacol Ther 93:303-305, 2013.